BCR and prostate cancer: This research team shares our view that Zr-89-labeled PSMA ligands appear to be effective in detecting prostate cancer in men with BCR and low PSA levels that may not be visible on scans using PSMA ligands labeled with short-lived radionuclides like Ga-68.